Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072903 · ClinicalTrials.gov registry record
The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 78
- Enrollment target
NCT01072903: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT01072903 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01072903 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
Study Summary
The research project addresses the following hypotheses (A) the normal balance of beneficial and detrimental commensal intestinal bacteria is deranged in IBS, with selective alterations in clinically defined patient subsets i.e., diarrhea predominant IBS (D-IBS) and post-infectious IBS (PI-IBS); (B) these changes in intestinal microflora are associated with sub-clinical mucosal inflammation and activation of the mucosal immune system; and (C) activation of the mucosal immune system leads to alterations in gastrointestinal (GI) functions (i.e., motility and sensation) and functional symptoms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-07 |
What the finished NCT01072903 record still lists
NCT01072903 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01072903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01072903 about?
NCT01072903 is a clinical study titled "The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)". The research project addresses the following hypotheses (A) the normal balance of beneficial and detrimental commensal intestinal bacteria is deranged in IBS, with selective alterations in clinically defined patient subsets i.e., diarrhea predominant IBS (D-IBS) and post-infectious IBS (PI-IBS); (B)...
What is the current status of trial NCT01072903?
This trial is currently completed. The enrollment target is 78 participants. The study started on 2009-01. Estimated completion is 2012-07.
Who is sponsoring clinical trial NCT01072903?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia